Information only — no products are sold on this website.
RT10 · Pen · Metabolic research — investigational
An investigational triple receptor agonist under clinical development. It is NOT approved for public use anywhere and should be regarded strictly as a research and clinical-trial compound.
Investigational compound
Retatrutide is investigational and is not approved for public use. It is not authorised for supply outside an approved clinical trial. This page is information only.
Retatrutide is an investigational multi-receptor agonist being evaluated in sponsor-run clinical trials. It is not an approved medicine in South Africa or elsewhere, and it is not authorised for public use or supply outside of an approved clinical trial.
Development programmes describe combined agonism at GIP, GLP-1 and glucagon receptors, pathways involved in appetite regulation and energy metabolism. Mechanistic descriptions here are informational only.
Phase 2 trial results have been published in peer-reviewed journals. Late-stage trials are ongoing. Investigational results do not constitute approval, and long-term safety data are not complete.
Evidence & Regulation
Every source below is a public, primary source — a literature index, a trials registry, or a regulator. They are reading directions for professionals, not endorsements, and they do not establish that any use of Retatrutide is approved, safe or appropriate.
LiteratureIndependent index of published studies. Most entries for research peptides are preclinical.
Clinical trialsShows whether the compound is being studied in authorised human trials, and at what phase.
RegulatorThe South African regulator. Health products must be registered or authorised before they may lawfully be sold here.
RegulatorCheck whether a marketing authorisation exists in the EU and read the assessment report if it does.
In South Africa, a product intended to treat, prevent or otherwise affect the functioning of the body is a medicine and must be registered with SAHPRA before it may lawfully be sold. An unregistered compound cannot be advertised or supplied to the public, regardless of the evidence behind it.
SAHPRA — medicines registrationWhere no registered alternative exists, a registered healthcare professional may apply to SAHPRA under Section 21 for authorisation to access an unregistered product for a named patient. That application is made by the clinician, not by the patient, and not by us.
Section 21 pathwayAny prescribing decision, dosing decision and dispensing step belongs to a registered healthcare professional and a licensed pharmacy. We publish reference information and analytical documentation only, and never dosing, protocols or self-administration guidance.
Non-approved substances are prohibited at all times under the World Anti-Doping Code, including many research peptides. Athletes under testing jurisdiction should treat every compound on this site as prohibited unless their governing body confirms otherwise.
WADA Prohibited ListA compound may be an approved medicine in one country, an investigational agent in a second, and an unregistered research chemical in a third. Always confirm the classification that applies where you practise before acting on any information here.
EMA medicines databaseInformation only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.